Herpes Simplex Virus (HSV-1) vector have great potential for gene therapy of neurological diseases and for studies in basic neuroscience. For example, HSV-1 vectors that express tyrosine hydroxylase have supported long-term (1 year) biochemical and behavioral correction of the 6-hydorxydopamine (6-OHDA) rat model of Parkinson's disease. However, these vectors have been complicated by side effects, such as cytopathic effects and immune responses, caused principally by the helper virus. Therefore, this laboratory recently developed a helper virus-free packaging system for these vectors. This system substantially addresses many of the previous problems with the vector system, but suffer from low titers. Therefore, this fellowship proposes two different approaches to increase the titers of the helper virus-free vector system. And then additional experiments will be performed to use these increased titers, in combination with improved vectors for expressing catecholamine biosynthetic enzymes, to correct the 6-OHDA rat model of PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32NS010805-03
Application #
6358315
Study Section
Special Emphasis Panel (ZRG1-BDCN-2 (02))
Program Officer
Murphy, Diane
Project Start
2000-09-21
Project End
Budget Start
2000-09-21
Budget End
2001-09-20
Support Year
3
Fiscal Year
2000
Total Cost
$39,232
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115